Avivagen Announces Largest Single Customer Purchase Order

•Largest purchase amount and longest duration purchase to-date
•Four tonne per month order secured
•Order follows five successful OxC-betaTM Livestock commercial trials conducted with various species over the past six months

Ottawa, ON / Business Wire/ May 3, 2021 / Avivagen Inc.  (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce that Meyenberg International Group, Avivagen’s consultant in Mexico, has entered into a contract which secures a four tonne per month recurring order for OxC-beta™ Livestock in Mexico.

The contract, which is 18 months from signing and includes an order for 500 Kgs delivered April 30th, is a commitment to purchase a minimum of four tonnes monthly, commencing in July, 2021 and ending October, 2022

“As we continue to see successful commercial trials conclude in those jurisdictions where OxC-beta™ Livestock is approved, we anticipate increased demand to follow, as has recently been demonstrated in Mexico and Thailand,” said Kym Anthony, Chief Executive Officer of Avivagen.  “With numerous other commercial trials currently underway and nearing completion, it is our belief that the continued success of such company conducted trials will help to accelerate the adoption and use of OxC-beta™ Livestock in approved jurisdictions and beyond. It is our belief that OxC-beta™ Livestock, once started by a customer, becomes core to their continued operations and will drive recurring orders for years to come.”

Meyenberg International Group
With a client base across North America and a well-earned reputation for enabling rapid growth for clients expanding into LATAM, Meyenberg’s experience in Mexico has enabled Avivagen to quickly establish and grow sales in the country since securing regulatory approval in August 2019.

About OxC-beta™ Technology and OxC-beta™ Livestock
Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about β-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia and Malaysia.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

About Avivagen
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance.  It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

Forward Looking Statements
This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions. Statements set out in this news release relating to the recurring nature of the orders under the contract described above, the anticipated date of fulfillment for the order described,  Avivagen’s expectation that the customer in question will live up to its contractual commitment to purchase product monthly, anticipated increase in demand for Avivagen’s products,  Avivagen’s expectation that commercial trials currently underway will be completed and yield positive results, the anticipated impact of the results of such trials on demand for product, expectations as to the recurring and long term nature of a customer’s purchases once they begin using Avivagen’s products and  the possibility for OxC-beta™ Livestock to replace antibiotics in livestock feeds as well as fill a critical need for health support in certain livestock applications where antibiotics are precluded are all forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, the order described may not result in new orders for Avivagen’s products,  the customer plans may change due to many reasons, timing of fulfillment of the order may be delayed beyond current expectation for a number of reasons which would push fulfillment and recognition of revenues for this order into a future quarter or cause such order to be cancelled, the parties to the contract described may not live up to their contractual commitments and/or may agree to amend such contract to reduce the commitments described above, demand for Avivagen’s products may not continue to grow and could decline,  commercial trials may not be completed and, if completed, may not yield results that are positive or which lead to additional demand for Avivagen’s products, except as otherwise stated, customers are under no obligation to continue using Avivagen’s products and Avivagen’s products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications, including human applications, and may not be widely accepted as a replacement for antibiotics in livestock feeds, , in each case due to many factors, many of which are outside of Avivagen’s control.  Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagen’s most recent management’s discussion and analysis of financial condition available at www.SEDAR.com. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:
Avivagen Inc.
Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Phone: 416-540-0733
E-mail: d.basek@avivagen.com

Kym Anthony
Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Head Office Phone: 613-949-8164
Website: www.avivagen.com

Copyright © 2021 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc

182 Responses

  1. I want to to thank you for this fantastic read!! I absolutely enjoyed every bit of it.
    I have got you book-marked to look at new things you post…

  2. When someone writes an paragraph he/she keeps the
    idea of a user in his/her brain that how a user can understand it.

    Therefore that’s why this post is amazing.
    Thanks!

  3. Every weekend i used to pay a quick visit this web site, as i wish for enjoyment, since
    this this web site conations truly nice funny data too.

  20. Hi fantastic blog! Does running a blog similar to this take a massive amount work?
    I’ve no understanding of computer programming but I had been hoping to start my own blog in the near future.
    Anyway, if you have any ideas or techniques for new blog owners please share.
    I understand this is off topic however I just wanted to ask.
    Thank you!

  23. An interesting discussion is worth comment.

    I do think that you need to write more on this issue, it may not be a taboo
    subject but typically people do not discuss these topics.

    To the next! Kind regards!!

  24. Hi there would you mind stating which blog platform you’re working with?
    I’m looking to start my own blog in the near future but I’m having a
    tough time deciding between BlogEngine/Wordpress/B2evolution and Drupal.

    The reason I ask is because your design and style seems different then most blogs and I’m looking for
    something completely unique. P.S Apologies for being off-topic but I
    had to ask!

  26. I really love your website.. Very nice colors & theme. Did you build this
    site yourself? Please reply back as I’m trying to create my very own website and want
    to find out where you got this from or exactly what the
    theme is called. Many thanks!

  85. Hi, I do think this is an excellent web site. I stumbledupon it 😉 I’m going to revisit
    yet again since I bookmarked it. Money and freedom is the greatest way to
    change, may you be rich and continue to help others.

  135. Heya i’m for the first time here. I found this board and I find It
    really helpful & it helped me out much. I’m hoping to
    offer one thing again and aid others such as you aided me.

  172. Hmm it seems like your site ate my first comment (it was super long) so I guess
    I’ll just sum it up what I wrote and say, I’m thoroughly enjoying your blog.
    I as well am an aspiring blog writer but I’m
    still new to everything. Do you have any tips and hints for newbie blog writers?
    I’d really appreciate it.

Leave a Reply

Your email address will not be published.